By modifying the tumor microenvironment and promoting immune cell infiltration, Bcl-2 inhibition may enhance responses to immune checkpoint inhibitors, unlocking new potential for immuno-oncology strategies [183]. This evidence concerns the gene BCL2 and neoplasm.